LightDeck Diagnostics Awarded $5.65M to Develop a Covid-19 Rapid Antigen Test
These funds will enable the company to develop a point-of-care antigen test that delivers results in less than 6 minutes.
Read MorePosted by Laurie Bonner | Feb 25, 2021 | Company News, Covid 19, POC Rapid Assays |
These funds will enable the company to develop a point-of-care antigen test that delivers results in less than 6 minutes.
Read MorePosted by Laurie Bonner | Feb 23, 2021 | Company News, Molecular Diagnostics |
Thermo Fisher Scientific is now calling for proposals dedicated to liquid biopsy research. Each proposal may receive an award worth up to $200,000 in reagents and funding.
Read MorePosted by Melanie Hamilton-Basich | Feb 22, 2021 | Covid 19 |
The test uses AnteoTech’s AnteoBind technology to support significantly improved sensitivity, and is the first covid-19 rapid self-test authorized by the FDA.
Read MorePosted by Laurie Bonner | Feb 22, 2021 | Compliance, Covid 19 |
The new guidances for medical product developers, specifically covering vaccines, diagnostics, and therapeutic products, address the emergence and potential future emergence of variants of SARS-CoV-2, the virus that causes covid-19.
Read MorePosted by Melanie Hamilton-Basich | Feb 19, 2021 | Colorectal, Research |
The study suggests that such liquid biopsies could help personalize treatment for oligometastatic colorectal cancer.
Read More